SLC5A2 and chronic kidney disease: This is suggested to be due to the increased prescribing of SGLT2 inhibitors to elderly patients as their safety was recognized and their efficacy in chronic heart failure and chronic kidney disease was reported, and the administration of these drugs increased not only for the purpose of improving HbA1c but also for the purpose of providing adjunctive benefits.